Hydronephrosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(13 intermediate revisions by one other user not shown)
Line 6: Line 6:
==Overview==
==Overview==


Common complications of hydronephrosis include infections, Hyperkalemia, Metabolic acidosis, and Distal renal tubular acidosis, hypertension and renal failure.
Common [[complications]] of [[hydronephrosis]] include [[infections]], [[hyperkalemia]], [[metabolic acidosis]], and distal [[renal tubular acidosis]], [[hypertension]] and [[renal failure]].


Prognosis is generally excellent, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==


===Natural History===
===Natural History===
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
*The [[symptoms]] of [[hydronephrosis]] can usually develop at any [[age]] depending on the underlying [[Causes|cause]] and present with [[symptoms]] such as, [[flank pain]]/[[Abdominal|abdomina]]<nowiki/>l [[pain]], [[nausea]], [[vomiting]], burning and painful [[micturition]], incomplete voiding.<ref name="pmid29283090">{{cite journal |vauthors=Sarhan OM, El Helaly A, Al Otay AH, Al Ghanbar M, Nakshabandi Z |title=Prenatally detected, unilateral, high-grade hydronephrosis: Can we predict the natural history? |journal=Can Urol Assoc J |volume=12 |issue=3 |pages=E137–E141 |date=March 2018 |pmid=29283090 |pmc=5869039 |doi=10.5489/cuaj.4587 |url=}}</ref>
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
*If left untreated for several weeks, the kidneys may become scarred, leading to kidney failure.
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


===Complications===
===Complications===
*Common complications of hydronephrosis include:<ref name="pmid3565506">{{cite journal |vauthors=Kozeny GA, Hurley RM, Vertuno LL, Bansal VK, Zeller WP, Hano JE |title=Hypertension, mineralocorticoid-resistant hyperkalemia, and hyperchloremic acidosis in an infant with obstructive uropathy |journal=Am. J. Nephrol. |volume=6 |issue=6 |pages=476–81 |date=1986 |pmid=3565506 |doi=10.1159/000167258 |url=}}</ref><ref name="pmid8558697">{{cite journal |vauthors=Chandar J, Abitbol C, Zilleruelo G, Gosalbez R, Montané B, Strauss J |title=Renal tubular abnormalities in infants with hydronephrosis |journal=J. Urol. |volume=155 |issue=2 |pages=660–3 |date=February 1996 |pmid=8558697 |doi= |url=}}</ref><ref name="pmid18295269">{{cite journal |vauthors=Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, Cho KS, Park YS |title=Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection |journal=J. Urol. |volume=179 |issue=4 |pages=1524–8 |date=April 2008 |pmid=18295269 |doi=10.1016/j.juro.2007.11.090 |url=}}</ref>
Common [[Complications During and Following Cardiac Catheterization and Percutaneous Coronary Intervention|complications]] of [[hydronephrosis|hydronephr]]<nowiki/>[[hydronephrosis|osis]] include:<ref name="pmid3565506">{{cite journal |vauthors=Kozeny GA, Hurley RM, Vertuno LL, Bansal VK, Zeller WP, Hano JE |title=Hypertension, mineralocorticoid-resistant hyperkalemia, and hyperchloremic acidosis in an infant with obstructive uropathy |journal=Am. J. Nephrol. |volume=6 |issue=6 |pages=476–81 |date=1986 |pmid=3565506 |doi=10.1159/000167258 |url=}}</ref><ref name="pmid8558697">{{cite journal |vauthors=Chandar J, Abitbol C, Zilleruelo G, Gosalbez R, Montané B, Strauss J |title=Renal tubular abnormalities in infants with hydronephrosis |journal=J. Urol. |volume=155 |issue=2 |pages=660–3 |date=February 1996 |pmid=8558697 |doi= |url=}}</ref><ref name="pmid18295269">{{cite journal |vauthors=Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, Cho KS, Park YS |title=Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection |journal=J. Urol. |volume=179 |issue=4 |pages=1524–8 |date=April 2008 |pmid=18295269 |doi=10.1016/j.juro.2007.11.090 |url=}}</ref><ref name="pmid4610948">{{cite journal |vauthors=King LR, Kazmi SO, Belman AB |title=Natural history of vesicoureteral reflux. Outcome of a trial of nonoperative therapy |journal=Urol. Clin. North Am. |volume=1 |issue=3 |pages=441–55 |date=October 1974 |pmid=4610948 |doi= |url=}}</ref><ref name="pmid20407913">{{cite journal |vauthors=Mesrobian HG |title=Urinary proteome analysis and the management of ureteropelvic junction obstruction |journal=Pediatr. Nephrol. |volume=25 |issue=9 |pages=1595–6 |date=September 2010 |pmid=20407913 |doi=10.1007/s00467-010-1521-2 |url=}}</ref>
** Infection secondary to obstruction
* [[Infection]] secondary to [[obstruction]]
** Electrolyte imbalance
* [[Electrolyte]] [[imbalance]]
*** Hyperkalemia
** [[Hyperkalemia]]
*** Metabolic acidosis
** [[Metabolic acidosis]]
*** Distal renal tubular acidosis
** Distal [[renal tubular acidosis]]
*** Excessive freewater diuresis
** Excessive [[Free-energy relationship|free]] [[water]] [[diuresis]]
** Hypertension
* [[Hypertension]]
** Real insufficiency and renal failure
* [[Renal]] [[Aortic insufficiency|insufficiency]] and [[renal failure]]
 
===Prognosis===
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
*[[Prognosis]] is generally good with early [[Treatment-resistant depression|treatment]]. Approximately 95% patients recover with timely intervention.<ref name="pmid29314159">{{cite journal |vauthors=Perlman S, Roitman L, Lotan D, Kivilevitch Z, Pode-Shakked N, Pode-Shakked B, Achiron R, Dekel B, Gilboa Y |title=Severe fetal hydronephrosis: the added value of associated congenital anomalies of the kidneys and urinary tract (CAKUT) in the prediction of postnatal outcome |journal=Prenat. Diagn. |volume=38 |issue=3 |pages=179–183 |date=February 2018 |pmid=29314159 |doi=10.1002/pd.5206 |url=}}</ref><ref name="pmid29161808">{{cite journal |vauthors=Renda R |title=Renal outcome of congenital anomalies of the kidney and urinary tract system: a single-center retrospective study |journal=Minerva Urol Nefrol |volume=70 |issue=2 |pages=218–225 |date=April 2018 |pmid=29161808 |doi=10.23736/S0393-2249.17.03034-X |url=}}</ref>
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 


==References==
==References==

Latest revision as of 18:05, 12 August 2018

Hydronephrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hydronephrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hydronephrosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hydronephrosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hydronephrosis natural history, complications and prognosis

CDC on Hydronephrosis natural history, complications and prognosis

Hydronephrosis natural history, complications and prognosis in the news

Blogs on Hydronephrosis natural history, complications and prognosis

Directions to Hospitals Treating Hydronephrosis

Risk calculators and risk factors for Hydronephrosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Common complications of hydronephrosis include infections, hyperkalemia, metabolic acidosis, and distal renal tubular acidosis, hypertension and renal failure.

Natural History, Complications, and Prognosis

Natural History

Complications

Common complications of hydronephrosis include:[2][3][4][5][6]

Prognosis

References

  1. Sarhan OM, El Helaly A, Al Otay AH, Al Ghanbar M, Nakshabandi Z (March 2018). "Prenatally detected, unilateral, high-grade hydronephrosis: Can we predict the natural history?". Can Urol Assoc J. 12 (3): E137–E141. doi:10.5489/cuaj.4587. PMC 5869039. PMID 29283090.
  2. Kozeny GA, Hurley RM, Vertuno LL, Bansal VK, Zeller WP, Hano JE (1986). "Hypertension, mineralocorticoid-resistant hyperkalemia, and hyperchloremic acidosis in an infant with obstructive uropathy". Am. J. Nephrol. 6 (6): 476–81. doi:10.1159/000167258. PMID 3565506.
  3. Chandar J, Abitbol C, Zilleruelo G, Gosalbez R, Montané B, Strauss J (February 1996). "Renal tubular abnormalities in infants with hydronephrosis". J. Urol. 155 (2): 660–3. PMID 8558697.
  4. Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, Cho KS, Park YS (April 2008). "Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection". J. Urol. 179 (4): 1524–8. doi:10.1016/j.juro.2007.11.090. PMID 18295269.
  5. King LR, Kazmi SO, Belman AB (October 1974). "Natural history of vesicoureteral reflux. Outcome of a trial of nonoperative therapy". Urol. Clin. North Am. 1 (3): 441–55. PMID 4610948.
  6. Mesrobian HG (September 2010). "Urinary proteome analysis and the management of ureteropelvic junction obstruction". Pediatr. Nephrol. 25 (9): 1595–6. doi:10.1007/s00467-010-1521-2. PMID 20407913.
  7. Perlman S, Roitman L, Lotan D, Kivilevitch Z, Pode-Shakked N, Pode-Shakked B, Achiron R, Dekel B, Gilboa Y (February 2018). "Severe fetal hydronephrosis: the added value of associated congenital anomalies of the kidneys and urinary tract (CAKUT) in the prediction of postnatal outcome". Prenat. Diagn. 38 (3): 179–183. doi:10.1002/pd.5206. PMID 29314159.
  8. Renda R (April 2018). "Renal outcome of congenital anomalies of the kidney and urinary tract system: a single-center retrospective study". Minerva Urol Nefrol. 70 (2): 218–225. doi:10.23736/S0393-2249.17.03034-X. PMID 29161808.

Template:WH Template:WS